NDAINJECTIONINJECTABLE
Approved
Oct 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INTRALIPID 10% (i.v. fat emulsion) by Fresenius Kabi is clinical pharmacology intralipid 10% is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. First approved in 1975.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Intralipid 10% is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the…
Pharmacologic Class:
Lipid Emulsion
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on INTRALIPID 10% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.